Aminolevulinic Acid
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Drug reference
capmatinib
MET kinase inhibitor · Antineoplastic agent
MET kinase inhibitorAntineoplastic agent
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
12 major
SEVERE in our sources
PREGNANCY
D
FDA category + note
Top interactionssee all 12 →
- Aminolevulinic AcidSevereDatabaseDDInter
- AmprenavirSevereDatabaseDDInter
- ApalutamideSevereDatabaseDDInter
- AtazanavirSevereDatabaseDDInter
Mechanism
Capmatinib is an orally bioavailable selective inhibitor of the MET kinase.
Indications
metastatic NSCLC with a mutation that leads to MET exon 14 skipping
Pharmacokinetics
Half-life
6.5 h
Metabolism
CYP3A4 (predominantly)
Side effects
Common
peripheral edemadyspepsiafatigue
Pregnancy & lactation
Pregnancy
D
Drug interactions
Amprenavir
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Apalutamide
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Atazanavir
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Berotralstat
Severe
Database
Drug interaction classified as: absorption
Source: DDInter
Boceprevir
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Bosentan
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Carbamazepine
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Cenobamate
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Ceritinib
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Clarithromycin
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Cobicistat
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Related guidelines
Other MET kinase inhibitor drugs
Ask House about capmatinib
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e·Verified: 2026-05-10 · House clinical team